telehealth

JD Health posts 23% revenue growth to 73.4B yuan with record 8.9% profit margin, but faces intensifying AI competition from Alibaba Health, Meituan, and others.

BLKBRD Asset Management fully exits $18M Hims & Hers position in Q4 2025, just before company reconciles with Novo Nordisk.

Universal Health Services to acquire Talkspace for $5.25/share in $835M deal, expanding virtual therapy access through 6,000 licensed professionals.

Cellhub launches AI-powered virtual care platform targeting 46% of rural hospitals operating at losses, combining 5G connectivity and managed services to address healthcare access crisis.

Online therapy market projected to grow from $4.38B (2025) to $17.34B (2035) at 14.76% CAGR, driven by mental health awareness and AI-enabled telehealth platforms.

Hims & Hers stock plunged 70% as GLP-1 market competition intensifies and growth slows. Despite challenges, company projects $2.8B 2026 revenue from diversified services.

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.

Hims stock down 75% due to Novo Nordisk lawsuit over semaglutide marketing, but analysts see 150% upside potential and record revenue coming.

Grief counseling market projected to grow from $3.67B to $5.83B by 2030, driven by digital health expansion and increased mental health awareness.

Remote patient monitoring market projected to grow from $36.6B (2026) to $164.5B (2035) at 18.18% annual growth, driven by chronic disease prevalence and aging populations.

Hims & Hers to acquire Eucalyptus for $1.15B, expanding into Australia, UK, and Germany. Deal closes mid-2026, marking major international growth push.